Akeso is back with more OS data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 2 September, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

presented by How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions

news Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patients Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial Superluminal secures $60M for Phase 1 of genetic obesity drug Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease In Focus China deaths reignite debate about using viruses to deliver CRISPR therapies

Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

in case you missed it 1. FDA conveys tougher clamp down of foreign trial data coinciding with China’s rise 2. CBER official overruled review team's rejection of new Replimune melanoma drug 3. News Briefing UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy 4. Teva reports a single-shot success in celiac disease, heating the IL-15 market 5. Exclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T 6. When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes 7. Mutate 'em all and see if you can sort 'em out Derek Lowe, In The Pipeline